GlassScriptPhysician profile
Tracy Mckenzie
NPI 1891171401
$7,779.22
in general payments reported to CMS, 2019-2025
49 companies · $1,479 in 2025
The $1,479 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,849 · 2022: $2,198 · 2023: $703 · 2024: $549 · 2025: $1,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,080 · Education: $369 · Long Term Medical Supply Or Device Loan: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,080.44 |
| Education | $368.98 |
| Long Term Medical Supply Or Device Loan | $282.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,374.97 | 2021-2025 | |
| Abbvie INC. | $602.67 | 2021-2025 | |
| Janssen Biotech, INC. | $499.97 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Pfizer INC. | $494.45 | 2021-2025 | |
| Seagen INC. | $400.69 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $384.57 | 2021-2024 | Imfinzi, Tagrisso, Enhertu |
| Merck Sharp & Dohme LLC | $326.03 | 2021-2025 | Keytruda |
| Celgene Corporation | $251.56 | 2021-2025 | Reblozyl, Breyanzi |
| Glaxosmithkline, LLC. | $243.89 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Incyte Corporation | $242.76 | 2021-2025 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $236.58 | 2021-2025 | Opdivo |
| Amgen INC. | $229.45 | 2021-2023 | Kyprolis |
| Karyopharm Therapeutics INC. | $212.29 | 2021-2022 | |
| Astellas Pharma US INC | $203.54 | 2021-2025 | Vyloy |
| Daiichi Sankyo INC. | $195.36 | 2021-2025 | Enhertu |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Mckenzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.